Table 1—

Clinical features of patients

Group 1
Group 2
%Mean ± SDMedian (range)%Mean ± SDMedian (range)
First evaluation
    Age (years)57.2 ± 14.758.5 (16.0–86.0)55.7 ± 13.358.0 (21.0–78.0)
    Men (%)51.355.6
    Weight (kg)84.1 ± 19.882.0 (46.0–181.8)81.8 ± 17.181.0 (48.0–135.0)
    BMI (kg/m2)29.9 ± 6.528.7 (20.0–52.1)28.9 ± 6.028.2 (20.0–52.1)
    Type of diabetes (type 1/type 2)17.2/79.820.0/78.9
    Duration of diabetes (years)8.8 ± 7.67.1 (0.2–71.7)8.1 ± 5.76.8 (0.2–24.8)
    A1C (%)7.9 ± 1.67.7 (4.8–13.4)8.0 ± 1.77.7 (5.8–13.4)
    FPG (mg/dl)167.8 ± 64.0155.5 (46.0–456.0)161.4 ± 58.4147.5 (46.0–328.0)
Last evaluation
    Age (years)65.4 ± 14.968.0 (20.0–89.0)69.6 ± 12.871.0 (32.0–89.0)
    Average weight (kg)84.5 ± 19.783.1 (45.1–183.1)83.6 ± 17.482.9 (47.1–131.7)
    Average BMI30.2 ± 6.428.9 (20.4–51.8)29.8 ± 6.028.7 (20.4–51.0)
    Type of diabetes (type 1/type 2)21.4/64.320.0/60.0
    Duration of diabetes (years)17.1 ± 8.816.2 (3.2–73.8)22.1 ± 5.921.3 (12.0–40.8)
    Duration of follow-up (years)8.0 ± 5.17.0 (1.0–18.0)13.8 ± 2.514.0 (9.0–18.0)
Average A1C (%)7.8 ± 1.27.7 (5.1–12.5)7.9 ± 1.07.7 (6.3–11.3)
Average FPG (mg/dl)169.6 ± 37.5163.8 (95.3–348.4)168.9 ± 30.3163.9 (118.2–259.5)
  • *

    * Group 1 patients (n = 238) are from the RDNS cohort, have had diabetes evaluated yearly or biyearly two or more times, and at first examination did not have polyneuropathy (DSPN) by nerve conduction criteria (defined for this study as ≥97.5th percentile of Σ 5 NC nds). At last examination, <238 had Σ 5 NC nds <97.5th (see text). Group 2 patients (n = 90) are a subset of group 1 patients and were evaluated six or more times. Less than 90 had Σ 5 NC nds <97.5th at last examination. FPG, fasting plasma glucose.